Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Abbott's flash glucose monitor to be made available on NHS

Posted on: 14 Sep 17

Abbott's FreeStyle Libre – a flash glucose monitor that allows diabetes patients to track their blood sugar without pricking – will be reimbursed by the NHS from 1 November, subject to local health economy approval.

The device's starter pack previously cost around £170, with readers for the sensors costing as much as £60, but will now be available for reimbursement via the NHS across England and Wales, NHS Scotland and Health and Social Care in Northern Ireland for people with type 1 and 2 diabetes who are intensively-using insulin.

The system uses a sensor the size of a £2 coin, worn on the back of the upper arm, to automatically read glucose levels. Clinical studies and real-world evidence have suggested that FreeStyle Libre users scan their glucose levels an average of at least 15 times per day, and that these higher rates of self-monitoring are strongly associated with improved glucose measures.

Chris Askew, Chief Executive of Diabetes UK, said: “Today’s announcement is fantastic news: Not since the transition from urine testing to finger-prick testing has there been such potential to transform the lives of people living with Type 1 and Type 2 diabetes through technology.

“Flash glucose monitoring can free people living with diabetes from the pain and rigour of frequent finger-prick testing, and puts them in greater control of their condition. In doing so, it has the potential to help prevent a host of devastating long-term complications. Today’s decision is testament to the commitment of campaigners, clinicians and policy makers to making this technology available."

He added: “The challenge now will be that everyone who could benefit from this technology is able to access it where they live; Diabetes UK will be looking to local decision makers to ensure people living with diabetes get proper access to this potentially life-changing technology.”

Editor's Details

Mike Wood

Last updated on: 14/09/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.